Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: ALNY

Alnylam Pharmaceuticals, Inc.

Healthcare | Biotechnology
$203.20
Market Cap$26.9B
Volume613.8K
EPS (FY2025)$2.33

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) is a $26.9B biotechnology company trading at $203.20 — 87.2× trailing earnings. Figures from SEC EDGAR and market feeds; updated 2026-10-11 00:51 UTC.

What Alnylam Pharmaceuticals, Inc. does

Alnylam Pharmaceuticals is a biopharmaceutical company that develops medicines using RNA interference, a naturally occurring biological process that silences disease-causing genes. The company has brought six RNAi-based medicines to market, including AMVUTTRA, ONPATTRO, GIVLAARI, OXLUMO, Leqvio, and Qfitlia, with more than twenty clinical programs in development. Alnylam uses delivery technologies such as GalNAc conjugates, lipid nanoparticles, and alternative approaches to enable the medicines to reach target tissues including the liver, central nervous system, and eye.

Summarized from Alnylam Pharmaceuticals, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Key facts

Quote
Price$203.20
Market cap$26.9B
Volume613.8K shares
Valuation
P/E (FY2025)87.21×
EV/EBITDA45.40×
EPS (FY2025)$2.33
Price/book34.09×
Return on equity39.76%

Revenue, margins & earnings

FY2021: net loss $853M on revenue $844M$844MFY2021FY2022: net loss $1.13B on revenue $1.04B$1.04BFY2022FY2023: net loss $440M on revenue $1.83B$1.83BFY2023FY2024: net loss $278M on revenue $2.25B$2.25BFY2024FY2025 Net income: $314MFY2025 Taxes & interest: $188MFY2025 Operating costs: $3.21B$3.71BFY2025
  • Net income
  • Taxes & interest
  • Operating costs
  • Net loss year
Annual revenue; bands show net, operating margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-10-06
  • 2026-10-06EVP, CLO and SecretarySale-1,758$398.9K
  • 2026-09-22Chief Executive OfficerAward107—
  • 2026-06-03DirectorSale-921$274.2K
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does Alnylam Pharmaceuticals, Inc. do?

Alnylam Pharmaceuticals is a biopharmaceutical company that develops medicines using RNA interference, a naturally occurring biological process that silences disease-causing genes.

What is ALNY's valuation?

ALNY trades at $203.20, 87.21× trailing earnings, 45.40× EV/EBITDA, as of 2026-10-11.

When did ALNY last file with the SEC?

Alnylam Pharmaceuticals, Inc.'s most recent SEC filing on record is a 10-Q filed 2026-07-30. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings and public market data feeds, fetched 2026-10-11 00:51 UTC. This page is also available as JSON at /api/data?ticker=ALNY and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for ALNY and 5,000+ tickers.

Create a free account — keep ALNY
For your agent
GET /api/data?ticker=ALNY

This page as JSON via rel="alternate" · REST API docs · MCP server (62 tools) · llms.txt